Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
AbbVie
Iambic Therapeutics, Inc
National Cancer Institute (NCI)
Beijing Biotech
Jazz Pharmaceuticals
Bayer
Exscientia AI Limited
Conjupro Biotherapeutics, Inc.
Arcus Biosciences, Inc.
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Vanderbilt-Ingram Cancer Center
Sotio Biotech Inc.
SillaJen, Inc.
858 Therapeutics, Inc.
EMD Serono
GlaxoSmithKline
SystImmune Inc.
Rondo Therapeutics
Institut Paoli-Calmettes
Eli Lilly and Company
Seagen Inc.
AstraZeneca
University of Michigan Rogel Cancer Center
BeOne Medicines
Psyence Australia Pty Ltd
Convalife (Shanghai) Co., Ltd.
University of California, Irvine
ViroMissile, Inc.
Yuhan Corporation
Seagen Inc.
AstraZeneca
Tizona Therapeutics, Inc
Essen Biotech
Ulsan University Hospital
NiKang Therapeutics, Inc.
Brigham and Women's Hospital
Poseida Therapeutics, Inc.
Baylor College of Medicine
MacroGenics
Nanjing Sanhome Pharmaceutical, Co., Ltd.
AstraZeneca
DualityBio Inc.
Daiichi Sankyo
SN BioScience
Takeda
Iksuda Therapeutics Ltd.
Second Life Therapeutics